Common Contracts
3 similar Contingent Convertible Debt Agreement contracts by Achieve Life Sciences, Inc.
2024 CONTINGENT CONVERTIBLE DEBT AGREEMENTContingent Convertible Debt Agreement • July 29th, 2024 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
Under the terms and conditions of the 2024 Contingent Convertible Debt Agreement among Borrower, FCB and Agent (as amended, modified, supplemented and/or restated from time to time, the “Agreement”), Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below. Attached are the required documents evidencing such compliance, setting forth calculations prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.
2023 CONTINGENT CONVERTIBLE DEBT AGREEMENTContingent Convertible Debt Agreement • May 17th, 2023 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
TO: First-Citizens Bank & Trust Company (“FCB”), as Agent, FCB, SVB Innovation Credit Fund VIII, L.P. and Innovation Credit Fund VIII-A, L.P., as Lenders
2021 CONTINGENT CONVERTIBLE DEBT AGREEMENTContingent Convertible Debt Agreement • December 22nd, 2021 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances